Literature DB >> 11176397

Increased prostatic lysophosphatidylcholine acyltransferase activity in human prostate cancer: a marker for malignancy.

F H Faas1, A Q Dang, J White, R Schaefer, D Johnson.   

Abstract

PURPOSE: Phospholipase A2 and lysophosphatidylcholine acyltransferase (LAT) constitute a deacylation-reacylation cycle that incorporates arachidonic acid into the lipid membrane. In a preliminary report we found increased LAT activity in malignant prostate tissue. We measured LAT activity in prostate tissue from a large number of patients undergoing prostatectomy.
MATERIALS AND METHODS: Prostate tissue from 93 patients undergoing radical prostatectomy for prostate carcinoma, 14 undergoing cystoprostatectomy for bladder cancer, 55 undergoing transurethral resection for benign prostatic hyperplasia and 11 with prostate cancer undergoing transurethral resection for relief of obstructive symptoms was analyzed for LAT activity.
RESULTS: In radical prostatectomy specimens using oleoyl coenzyme A as substrate mean increase in LAT activity between malignant and benign portions of the same specimen was 0.68 +/- 0.12 nmol./mg. protein per minute (p <0.00001). In all radical prostatectomy specimens analyzed LAT activity was 43% higher in the malignant than benign portions (2.25 +/- 0.15 versus 1.57 +/- 0.11 nmol./mg. protein per minute, p <0.001). In the 10 benign prostate specimens obtained from cystoprostatectomy mean LAT activity was 1.12 +/- 0.18 nmol./mg. protein per minute, which was significantly lower than that of benign portions of radical prostatectomy (p <0.05). LAT activity in benign cystoprostatectomy specimens was significantly higher than that in the 50 benign transurethral resection specimens (0.54 +/- 0.05, p <0.01), possibly due to heat damage in transurethral resection specimens during collection. However, LAT activity in transurethral resection specimens from patients with known prostate cancer was similarly increased. Similar results were obtained using arachidonoyl coenzyme A.
CONCLUSIONS: We demonstrated increased LAT activity in malignant tissue from patients with prostate cancer. Thus, the deacylation-acylation remodeling cycle may be enhanced to provide more arachidonic acid to meet the demand for prostaglandin E2 synthesis in malignant tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176397     DOI: 10.1097/00005392-200102000-00026

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.

Authors:  Xinchun Zhou; Thomas J Lawrence; Zhi He; Charles R Pound; Jinghe Mao; Steven A Bigler
Journal:  Exp Mol Pathol       Date:  2011-11-11       Impact factor: 3.362

2.  Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells.

Authors:  Liza Barki-Harrington; Angela L Bookout; Gaofeng Wang; Maria E Lamb; L M Fredrik Leeb-Lundberg; Yehia Daaka
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

3.  Marine phospholipids--a promising new dietary approach to tumor-associated weight loss.

Authors:  Lenka A Taylor; Lars Pletschen; Jann Arends; Clemens Unger; Ulrich Massing
Journal:  Support Care Cancer       Date:  2009-04-29       Impact factor: 3.603

4.  High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.

Authors:  Katharina Grupp; Stella Sanader; Hüseyin Sirma; Ronald Simon; Christina Koop; Kristina Prien; Claudia Hube-Magg; Georg Salomon; Markus Graefen; Hans Heinzer; Sarah Minner; Jakob R Izbicki; Guido Sauter; Thorsten Schlomm; Maria Christina Tsourlakis
Journal:  Mol Oncol       Date:  2013-07-19       Impact factor: 6.603

5.  Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.

Authors:  Gao-Song Wu; Sheng-Quan Zou; Zheng-Ren Liu; Zhao-Hui Tang; Ju-Hua Wang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 6.  Advances in Lipidomics for Cancer Biomarkers Discovery.

Authors:  Francesca Perrotti; Consuelo Rosa; Ilaria Cicalini; Paolo Sacchetta; Piero Del Boccio; Domenico Genovesi; Damiana Pieragostino
Journal:  Int J Mol Sci       Date:  2016-11-28       Impact factor: 5.923

7.  Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.

Authors:  Yiqing Du; Qiang Wang; Xingzhong Zhang; Xiaofeng Wang; Caipeng Qin; Zhengzuo Sheng; Huaqi Yin; Changtao Jiang; Jing Li; Tao Xu
Journal:  J Exp Clin Cancer Res       Date:  2017-05-12

8.  Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.

Authors:  Kyung-Hee Kim; Jungnam Joo; Boram Park; Sang-Jae Park; Woo Jin Lee; Sung-Sik Han; Tae Hyun Kim; Eun Kyung Hong; Sang Myung Woo; Byong Chul Yoo
Journal:  Oncotarget       Date:  2017-11-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.